Marker Therapeutics, Inc.
MRKR Nasdaq
SEC CIK 1094038
Follow Marker Therapeutics
Weekly email: filings, results
Net income
−$1.8M
+7.7% vs same quarter last year
EPS, diluted
−$0.10
+16.7% vs same quarter last year
Operating cash flow
−$2.5M
+8.8% vs same quarter last year
Operating income
−$3.2M
+4.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $3.5M | −$12.2M |
| FY24 | $6.6M | −$10.7M |
| FY23 | $3.3M | −$8.2M |
| FY22 | $3.5M | −$29.9M |
| FY21 | $0 | −$41.9M |
| FY20 | $500K | −$28.7M |
| FY19 | $213.2K | −$21.4M |
| FY18 | $206K | −$148M |
| FY17 | $183.1K | −$11M |
| FY16 | - | −$2.5M |
| FY15 | - | −$34.1M |
| FY14 | - | −$30.9M |
| FY13 | - | −$5.5M |
| FY12 | - | −$5.9M |
| FY11 | - | −$2M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −363.5% | −343% |
| FY24 | −168.7% | −162.8% |
| FY23 | −440.4% | −248.8% |
| FY22 | −563.3% | −851.9% |
| FY21 | - | - |
| FY20 | −5777.2% | −5741.2% |
| FY19 | −10567.3% | −10050.9% |
| FY18 | −71930.1% | −71826.3% |
| FY17 | −6271.1% | −5999.1% |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | −$18.7M |
| FY18 | −$14.6M |
| FY17 | −$8.4M |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | $71.7K |
| FY17 | $310.5K |
| FY16 | $0 |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Marker Therapeutics
- Healthcare median
Show the numbers
| Year | Marker Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −343% | −30.6% |
| FY24 | −162.8% | −47% |
| FY23 | −248.8% | −58% |
| FY22 | −851.9% | −80.4% |
| FY21 | - | −71.9% |
| FY20 | −5741.2% | −62.2% |
| FY19 | −10050.9% | −46.3% |
| FY18 | −71826.3% | −49.6% |
| FY17 | −5999.1% | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |